Bifogade filer
Kurs & Likviditet
Kalender
Tid* | ||
2025-02-27 | 08:30 | Bokslutskommuniké 2024 |
2024-11-28 | 08:30 | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-07-01 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2024-06-30 | - | Årsstämma |
2024-05-30 | - | Kvartalsrapport 2024-Q1 |
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-27 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-06-30 | - | Årsstämma |
2023-05-11 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2023-02-24 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-06-13 | - | Årsstämma |
2022-05-09 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-12-16 | - | Extra Bolagsstämma 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-06-04 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2021-06-03 | - | Årsstämma |
2021-04-23 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-06-05 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2020-06-04 | - | Årsstämma |
2020-04-21 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-12 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2019-05-22 | - | Årsstämma |
2019-04-26 | - | Kvartalsrapport 2019-Q1 |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-23 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2018-05-22 | - | Årsstämma |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-03-22 | - | Split GABA 4:1 |
2018-03-07 | - | Extra Bolagsstämma 2017 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-13 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-22 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2017-05-19 | - | Kvartalsrapport 2017-Q1 |
2017-05-19 | - | Årsstämma |
2017-02-14 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-06-07 | - | Årsstämma |
2016-05-24 | - | Kvartalsrapport 2016-Q1 |
2016-04-04 | - | Extra Bolagsstämma 2016 |
2016-02-22 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
2015-08-21 | - | Kvartalsrapport 2015-Q2 |
2015-05-22 | - | Kvartalsrapport 2015-Q1 |
2015-02-17 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
2015-02-13 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Gabather AB ( www.gabather.com) has received the electroencephalography (EEG) analysis of the 17 human healthy volunteers involved in the target engagement study with the lead clinical candidate GT-002 as part of the collaboration with MINDIG (https://mindig.io/company/). The quantitative analysis of the recordings showed statistically significant increase induced by GT-002 on the EEG alpha frequency band power. MINDIG will continue the EEG data analysis and expects to deliver new analysis of the data early next year.
" The EEG data analysis shows that our drug candidate GT-002 , when given orally, modifies the brain activity in a specific manner distinct from competitor compounds and generates a selective brain activity modulation specific for GT-002. This enables us to explore new indications for GT-002 in mental health - what a great way to end the year -and we look forward to patient studies in 2024" says Michael Robin Witt, CEO of Gabather.
Contact Information
Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: mrw@gabather.com
About Gabather
Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders. The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients.
For more information, please visit: www.gabather.com
Certified Adviser
Corpura Fondkommission AB
Phone: +4672-252 34 51
Email: ca@corpura.se
www.corpura.se